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Abstract
Background: Epithelial ovarian cancer is one of the most malignant cancers in women because metastasis occurs
in the most of patients by the time of diagnosis. Cancer cells have strong capacity to form angiogenesis or
vasculogenic mimicry, which plays the major role in its malignant phenotype. Vasculogenic mimicry might
contribute to the failure of the angiogenesis-targeted therapy strategies. Under the microenvironment of the
tumor, hypoxia is the most common phenomena because of the vast energy and oxygen consuming. In the
present study, the endothelial-like cells induced by hypoxia from SKOV-3 and ES-2 ovarian cancer cells were
harvested to investigate the changes in their biological behaviors.
Methods: The endothelial-like cells from SKOV-3 and ES-2 cells were harvested by laser capture microdissection.
The biological behaviors of the endothelial-like cells, including proliferation, cell cycle, apoptosis, invasion and
telomerase activity were determined by MTT, FCM, Transwell chamber and TRAP-ELISA methods. HIF-1a is the
most important factor for the behavior changes under hypoxic condition. Some other genes relative to biological
behaviors are also changes following the changes of HIF-1a. In order to elucidate the underlying mechanisms for
these changes by hypoxia, the relative genes expressions including HIF-1a, CyclinD1, Flk-1, VEGF, p53 and V-src
were determined by real-time PCR.
Results: SKOV-3 and ES-2 cells were resistant to hypoxia by adoption of proliferation, apoptosis, differentiation and
invasion. Combined with other studies, the more poorly cancer cells differentiate, the more strongly cells are
resistant to hypoxia, the more possible to form vasculogenic mimicry. The changes in the expression of HIF-1a,
and HIF-1a-dependent VEGF, Flk-1, Cyclin D1, and HIF-1a-independent p53 have been involved in this process.
Conclusions: HIF-1a took an important role in the behavioral changes of SKOV-3 and ES-2 cells by hypoxia. At the
same time, other mechanisms were also involved in this process.
Background
Epithelial ovarian cancer (EOC) has the ~50% mortality
rate, making it the leading cause of death from gyneco-
logical cancers [1,2]. In most patients, metastasis occurs
within the peritoneum by the time of diagnosis.
Although the cellular and molecular mechanisms of
tumor growth and metastasis are not completely under-
stood, it is established that formation and growth of
new blood vessels is critical for tumor survival, growth,
and expansion [3]. Numerous studies have demonstrated
that the more vasculogenesis, the more malignant of the
tumors. Thus, efforts to reduce the growth and spread
of ovarian cancer have recently focused on angiogenesis
because they are dependent in part on the formation of
adequate vascular support [4], which means forming or
sprouting of new endothelium-lined vessels from pre-
existing vessels [5].
The traditionally recognized mechanism for tumor
vasculature and perfusion has been thought to be
endothelial cells-lined vascular networks [6]. However,
recent study has found that some aggressive tumor cells
generate vasculogenic-like channels in the absence of
endothelial cells or fibroblasts [7]. The formation of the
patterned microcirculation is termed vasculogenic
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aggressive tumor cells are able to generate not-endothe-
lial cell-lined channels delimited by extracellular matrix
in vitro [7-9]. That’st h er e a s o nw h yi ti sd i f f i c u l tt o
control ovarian cancer with angiogenesis-targeted ther-
apy strategies [9] which have no positive effect on such
vasculogenesis.
Hypoxia is one of the major important factors in
angiogenesis descried by Folkman for it is associated
with resistance to chemo- and radio-therapies. The
development of tissue hypoxia is characteristically
observed as malignant tumor rapidly increase in size.
Such hypoxic conditions exert selective pressure on can-
cer cells, and the ability of tumor cells to survive in a
hypoxic microenvironment has been associated with a
poor prognosis and resistance to therapy [10]. One of
the most critical and best characterized responses to
hypoxia is the induction of vascular endothelial growth
factor (VEGF), and hypoxia-inducible factor-1 (HIF-1) is
a well-established mediator in this process. Our previous
studies have demonstrated that the ovarian cancer cells
could be induced into endothelial-like cells which have
the specific characteristics of endothelial cells at the
condition of hypoxia in vivo and in vitro [11-13], in
which HIF-1a played a vital role.
As it is known that the endothelial-like cells (EL) ori-
gin from cancer cells are different from the endothelial
cells. However, the detailed difference and the mechan-
isms are not well understood. In the present study, we
set out to determine some biological behaviors of the
ELs from two malignant ovarian cancer cell lines,
SKOV-3 and ES-2, such as the proliferation, cell cycle,
apoptosis, the activity of telomerase and invasion. At the
same time, we compared these biological behaviors with
traditional endothelial cell, human umbilical vein
endothelial cell (HUVEC) and the original cancer cells.
Further, we tried to explore the underlying mechanisms
by detection the expression of some relative genes.
Methods
Cell culture
Human epithelial ovarian carcinoma cell lines SKOV-3
and ES-2 were purchased from American Type Culture
Collection (ATCC, Manassas, VA), and were maintained
in McCoy’s 5a. Primary human umbilical vein endothe-
lial cells (HUVEC) were isolated from umbilical vein
and cultured as described previously [14]
Three-dimensional cultures and hypoxic treatment
Thirty microliters of Matrigel (B&D, Bedford, MA) were
dropped onto each glass coverslip in a 12-well culture
plate and polymerized for 1 h at room temperature, fol-
lowed by 30 min’s incubation at 37°C in a humidified
5% CO2 incubator, as described previously [15]. Tumor
cells (1 × 10
4) were seeded onto the three-dimensional
gel. The medium supplied with 15% FBS was changed
every 36 h. Hypoxic condition was created by flushing
5% CO2 and 95% N2 through a modified chamber
(Mitsubishi, Japan), until O2 concentration was reduced
to 1%, measured with a Mini oxygen meter. The culture
system was sealed and incubated at 37°C [16]. The cells
were treated with 50 nM Sirolimus (Sigma, St. Louis,
M O )i nD M S Ot oi n h i b i tt h er o l eo fH I F - 1 a under
hypoxia when necessary.
Proliferation assay
For the proliferation assay, 1 × 10
4 SKOV-3, ES-2 and
HUVEC cells, were seeded into a flat bottom 96-well
plate and incubated at 37°C for 3 and 7 d under nor-
moxia or hypoxia (1% O2) respectively, prior to the
addition of 20 μL of MTT solution (5 mg/ml in PBS).
After incubated for additional 4 h at 37°C, absorbance
at 490 nm was measured with a multi-function reader
(Tecan GENios, Zurich, Switzerland) to determine cell
viability.
Cell cycle and apoptosis assay
Cell cycle and apoptosis assay were performed on cells
with or without hypoxia treatment (for 3 or 7 d) to
determine whether hypoxia regulates the growth phase
and apoptosis of epithelial ovarian cells. Cells were tryp-
sinized and centrifuged at 300 × g (1000 rpm) for
5 min, then resuspended (1 × 10
6 cells/ml) and fixed
with 70% ice-cold ethanol for 30 min, followed by cen-
trifuged, washed and resuspended in 500 μlP B Sc o n -
tained 10 μl of DNase free RNase (final concentration is
1‰). After 30 min incubation, pyridine iodide (PI, 0.05
mg/ml) was added to the solution to incubate for an
additional 15 min in the dark and filtered by a nylon
mesh to remove cell clusters. The fluorescence of PI
was measured using FACS Calibur Flow Cytometer
(Becton-Dickinson, San Jose, CA). Cell subpopulations
in G0/G1, S and G2/M phases and apoptosis were
calculated by gating analysis based on differences in
DNA content. At least 20000 cells were analyzed per
sample. Cell proliferation characters were indexed by
the ratio in S-phase.
Invasion assay
Invasion assays were performed in a 24-well transwell
chamber (Costar, Bodenheim, Germany) as previously
described [17]. Briefly, the 8 μmp o r ei n s e r t sw e r e
coated with 15 μg of Matrigel. Cells were seeded to
coated filters (5 × 10
4 cells/filter) in 200 μLo fs e r u m -
free medium in triplicate. Another 500 μL of serum-free
media was added in the lower parts of the chambers.
After 7d’s incubation under hypoxia, the upper Matrigel
coated surface was wiped off using a cotton swab. Cells
Zhu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:124
http://www.jeccr.com/content/29/1/124
Page 2 of 8migrated through the filters were fixed, stained with
Giemsa (Sigma, St. Louis, MO), photographed, and
counted.
Laser capture microdissection
Fifteen microliters of Matrigel were mounted on ethy-
lene vinyl acetate (EVA) membrane (Leica, Wetzlar,
Germany) with frame instead of coverslip in 9-cm dishes
and treated to establish three-dimensional culture as
described above. The density of tumor cells seeded onto
gel was adjusted to 1 × 10
5.A f t e r7d ,s a m p l e so nE V A
membrane were washed with PBS-DEPC and air-dried,
channels formed by endothelial-like cells (ELs) were
selected by microscopy and microdissected with laser
capture microdissection (LCM) system (Leica). About
1,500-2,000 ELs were laser-captured from each EVA
membrane. The cells were immersed in digestion buffer
for quantitative real-time reverse transcription polymer-
ase chain reaction (RT-PCR) and telomerase activity
assay.
Quantitative real-time RT-PCR
Total RNA was extracted from 2 × 10
4 cells (including
HUVEC, SKOV-3, SKOV-3 EL, ES-2, ES-2 EL, or the
SKOV-3 or ES-2 cells treated by 50 nM Sirolimus)
using TRIzol reagent (Invitrogen, Carlsbad, CA). Ali-
quots of RNA were reverse transcribed to cDNA using a
Superscribe First-Strand synthesis system (Invitrogen).
Real-time PCR analysis was performed to quantify
mRNA expression of HIF-1a, VEGF, Flk-1, Cyclin D1,
p53, and V-src by a Rotor-Gene3000 PCR system (Cor-
bett, Australia) using SYBR-Green PCR Master mix
(Qiagen, Hilden, Germany). The PCR reaction consisted
of 12.5 μl of SYBR-Green PCR Master mix, 1.0 μl of for-
ward and reverse primers (0.4 μM final concentration),
and 2.0 μl of 1:10-diluted template cDNA in a total
volume of 25 μl. Amplification was initiated at 50°C for
2 min, 95°C for 70 sec, followed by 40 cycles of 95°C for
20 sec, 58°C for 20 sec, and 72°C for 30 sec. To verify
only a single product produced, a dissociation protocol
was added after thermocycling. The assay included a
no-template control, a standard curve of four serial dilu-
tion points (in steps by 10-fold) of a cDNA mixture. All
data were controlled by Rotor-Gene software (version
6.0) for quantity of RNA input, an endogenous reference
gene (b-actin) was performed as control in the same
reverse transcription reaction. Data were presented as
the means ± S.E from three separate experiments. The
primers used in this experiment were shown in Table 1.
All primers were designed using Primer3 web software
(Whitehead Institute, Cambridge, MA) and were synthe-
sized by Sangon Biological Engineering Technology and
Service Co., Ltd. (Shanghai, P.R. China).
Telomerase activity assay
The telomerase activity of all the cells (including
HUVEC, SKOV-3, SKOV-3 EL, ES-2, ES-2 EL, or the
SKOV-3 or ES-2 cells treated by 50 nM Sirolimus) was
tested by telomerase repeat sequence amplification-
enzyme linked immunosorbent assay (TRAP-ELISA)
using the kit from Huamei Biotechnology Co., Ltd.
(Shanghai, China) according to the manufacturer’s
instruction.
Statistical analysis
ANOVA analysis or paired-samples t-test were per-
formed to identify differences, using SPSS11.5 statistical
software (Lead, US). Statistical significance was assumed
at P < 0.05, P-values are presented as two-tailed.
Results
The morphology of the endothelial-like cells from ovarian
cancer shows similarities to HUVEC endothelial cells
To investigate the morphology of the endothelial-like
cells from ovarian cancer induced by hypoxia, the
SKOV-3 and ES-2 cells were cultured in the 3-dimen-
sional Matrigel system on EVA membrane under 1% O2
for 7 d before harvested by LCM. The morphology of
the endothelial-like cells induced by hypoxia were pic-
t u r e db ym i c r o s c o p ea n ds h o w ni nF i g u r e1 .A si t
shown, after incubated under hypoxia, the ovarian can-
cer cells extended and reshaped, developed ELs and
connected with each other (A and B), eventually form-
ing network structures and channels (C and D). The
original and microdissected by LCM of the single cell
were shown in Fig. 1A and 1B, Fig. 1C and 1D indicated
the original and microdissected grouped cells.
The biological behaviors such as proliferation, cell cycle,
apoptosis and invasion of SKOV-3, ES-2 and HUVEC cells
are changed by hypoxia
In order to elucidate the biological behaviors changes in
SKOV-3, ES-2 and HUVEC cells by hypoxia, the prolif-
eration, cell cycle, apoptosis and invasion were detected
by MTT, FCM and transwell chamber after induced by
hypoxia for 3 or 7 d. As shown in Fig. 2A, the prolifera-
tion of SKOV-3 was inhibited significantly on 3rd d
while there was no difference after 7d’s incubation. As
for the proliferation of ES-2 cells, there has no signifi-
cant difference after incubation under hypoxia. The pro-
liferation of HUVEC cells were inhibited by incubation
u n d e rh y p o x i af o r3da n df u r t h e ri n h i b i t e da f t e r7d ’s
incubation.
The percent of cells in S-phase and apoptosis after
incubation for 3 or 7 d under hypoxia were shown in
Fig. 2B and 2C. As they shown, in the case of SKOV-3
and ES-2 cells, the percent in S-phase were decreased
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tion, however, there had no difference in S-phase and
apoptosis after 7 d’s incubation of the two cell lines. On
the other hand, the percent of S-phase of HUVEC cells
was decreased and that of apoptosis was increased after
both 3 and 7 d’s incubation.
The numbers of cell migrated through basement
membrane of the transwell chamber were shown in Fig.
3D (after 3 d’s incubation) and 3E (after 7 d’si n c u b a -
tion). Compared to normoxia control, the numbers
decreased significantly in SKOV-3 after 3 and 7 d’s
incubation under hypoxia while it decreased significantly
in ES-2 only after 3 d’s incubation. The numbers of
HUVEC cells were decreased significantly after both 3
and 7 d’s incubation.
The activities of telomerase of SKOV-3, ES-2 and HUVEC
cells are changed by hypoxia
In order to study the malignant of the ovarian cancer
cells, the activities of telomerase of SKOV-3, ES-2 and
Table 1 The sequences of the primers used in the experiment
Gene Sense Antisense Product (bps)
HIF1a TGCACAGGCCACATTCACGT GTTCACAAATCAGCACCAAGC 97
Flk-1 ACAGTGGTATGGTTCTTGCCTCA GTAGCCGCTTGTCTGGTTTGA 140
VEGF TCACCAAGGCCAGCACATAG GGGAACGCTCCAGGACTTAT 166
Cyclin D1 GATGCCAACCTCCTCAACGAC CTCCTCGCACTTCTGTTCCTC 171
V-src CACTCGCTCAGCACAGGACAG AGAGGCAGTAGGCACCTTTCG 196
P53 GCTGCTCAGATAGCGATGGTC CTCCCAGGACAGGCACAAACA 298
b-actin CCTGTACGCCAACACAGTGC ATACTCCTGCTTGCTGATCC 211
Figure 1 The morphology of the ELs from ovarian cancer induced by hypoxia and microdissected by LCM. The ovarian cancer cells were
cultured in 3-dimisonal Matrigel system on EVA membrane under hypoxia for 7 d before harvest. The pictures were taken under the light
microscope. A and B. The original and after microdissected by LCM of the single cell. C and D. The original and after microdissected by LCM of
the grouped cells. Magnification X200. Arrow: The morphology of the cells after microdissection.
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hypoxia with Sirolimus were detected by TRAP-ELISA.
As shown in Table 2, the activities of telomerase were
positive in all the SKOV-3 endothelial-like cells, SKOV-
3 under normoxia or with Sirolimus. The activities of
telomerase were negative in ES-2 endothelial-like cells
and ES-2 with Sirolimus but positive in ES-2 under nor-
moxia. As we expected, the activity of telomerase was
negative in HUVEC cells.
The different expression of HIF-1a, CyclinD1, VEGF, Flk-1,
p53 and V-src mRNA in SKOV-3, ES-2 and HUVEC cells
after incubation under hypoxia
In order to elucidate the underlying mechanisms for the
biological behaviors changes of the ELs by hypoxia, the
mRNA expression of HIF-1a, CyclinD1, VEGF, Flk-1,
p53 and V-src in SKOV-3, ES-2 and HUVEC cells incu-
bated under hypoxia, normoxia or hypoxia with Siroli-
mus were detected by Real-time PCR. The genes
expression mentioned above in SKOV-3 and SKOV-3
relative cells were shown in Fig. 3A and Fig. 3B indi-
cated the genes expression in ES-2 and ES-2 relative
cells.
As shown in Fig. 3, HIF-1a mRNA expression in both
of the two tumors’ ELs was significantly higher than
that in the cells under normoxia and with Sirolimus,
and than that in HUVEC cells.
VEGF mRNA expression in both of the two tumors’
ELs was significantly higher than that in the cells under
normoxia and with Sirolimus, but was greatly lower
than that in HUVEC cells.
Flk-1 mRNA expression in both of the two tumors’
ELs was significantly higher than that in the cells under
normoxia, but was greatly lower than that in HUVEC
cells. On the other hand, Flk-1mRNA expression in ES-
2 endothelial-like cells was significantly higher than that
in cells treated with Sirolimus, however, there was no
difference in Flk-1 mRNA expression between SKOV-3
endothelial-like cells and SKOV-3 cells treated with
Sirolimus.
Figure 2 The proliferation, cell cycle, apoptosis, invasion of SKOV-3, ES-2 and HUVEC cells induced by hypoxia.T h eS K O V - 3 ,E S - 2a n d
HUVEC cells were cultured for 3 or 7 d in normoxia or hypoxia conditions before proliferation, cell cycle (S-phage), apopotosis and invasion
detected by MTT, FCM (for cell cycle and apoptosis) and Transwell as shown in methods. A. The proliferation of three cells by MTT. B. The S-
phase ratio in three cells by FCM. C. The apoptosis of three cells detected by FCM. D and E. The numbers of cells invasion through the
membrane indicated by Transwell after incubated for 3 days (D) or 7 days (E). Data were shown in Mean ± S.D. from three separate experiments
with the similar result. * and ** indicates P < 0.05 and P < 0.01 vs. Normoxia.
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tumors’ ELs was greatly lower than that in the cells
under normoxia, while there was no difference in Cyclin
D1 mRNA expression in the cells treated with Sirolimus
and HUVEC cells.
p53 mRNA expression in both of the two tumors’ ELs
was significantly higher than that in the cells under nor-
moxia and in HUVEC cells, however, there was no sig-
nificant changes after treated with Sirolimus.
V-src mRNA didn’t express in all kinds of cells under
hypoxia or normoxia.
Discussion
In the present study, we induced two ovarian cancer cell
lines, SKOV-3 and ES-2, to endothelial-like cells by
hypoxia and harvested the ELs by LCM. On the base of
our previous study [11], the ELs have the specific char-
acteristics of endothelial cells, such as expressing CD34,
vWF and uptaking acLDL. Here, we detected the biolo-
gical behaviors of the ELs and compared with the
HUVEC endothelial cells and the original cancer cells.
As shown in the results, under the condition of
hypoxia, the cancer cells’ growth was inhibited in the
short period (3 d), however, after the long-time hypoxia
(7 d) incubation, the cells were recovered to grow. The
results of the proliferation assay, cell cycle and apoptosis
assay demonstrated these. HUVEC, on the other hand,
could not endure hypoxia, which showed inhibited prolif-
eration, reduced S-phase ratio, and increases in apoptosis
under the condition of hypoxia. As indicated by previous
studies [10,18], the more aggressive of the cancer, the
more strongly the cells could resistant to hypoxia. Under
the condition of hypoxia, the cancer cells could change
some characteristics into ELs to form VM, and then the
tumor could perfuse itself independent of angiogenesis.
Tumors exhibiting in VM related to more aggressive
tumor biology and increased tumor-related mortality
[19,20]. Invasion through the basement membrane is one
of the features of the aggressive tumor. Under the condi-
tion of hypoxia, the SKOV-3 and ES-2 ovarian cancer
cells reduced the ability to invasion at first and then
recovered to normal level after long-time hypoxia.
Telomerase, an enzyme complex that binds the chro-
mosome ends (telomeres) and maintains telomere length
Figure 3 The genes expression in SKOV-3, ES-2, ELs from cancer cells and HUVEC induced by hypoxia. The SKOV-3, ES-2 and HUVEC cells
were cultured for 7 d in normoxia or hypoxia conditions before harvested for the expression of HIF-1a, VEGF, Flk-1, CyclinD1, p53 and V-src
genes detected by Real-time PCR. A. The genes expression in SKOV-3 and relative cells by Real-time PCR. B. The genes expression in ES-2 and
relative cells by Real-time PCR. SKOV-3 EL: the endothelial-like cells induced from SKOV-3 cells; SKOV-3+Si: the SKOV-3 cells treated by Sirolimus
under hypoxia; ES-2 EL: the endothelial-like cells induced from ES-2 cells; ES-2+Si: the ES-2 cells treated by Sirolimus under hypoxia; *, ^, and &
indicates that P < 0.05 vs.HUVEC, SKOV-3 (or ES-2) and SKOV-3+Si (or ES-2+Si); **, ^^, and && indicates that P < 0.01 vs.HUVEC, SKOV-3 (or ES-2)
and SKOV-3+Si (or ES-2+Si).
Table 2 The activity of telomerase in different cells
CELLS RESULT
HUVEC -
SKOV-3 +
SKOV-3 EL +
SKOV-3+Si +
ES-2 +
ES-2 EL -
ES-2+Si -
SKOV-3 EL: the endothelial-like cells induced from SKOV-3 cells; SKOV-3+Si:
the SKOV-3 cells treated by Sirolimus under hypoxia; ES-2 EL: the endothelial-
like cells induced from ES-2 cells; ES-2+Si: the ES-2 cells treated by Sirolimus
under hypoxia.
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ulose cells, germline stem cells, and neoplastic cells in
the ovary, but is absent from differentiated or aged cells.
Activation of telomerase in the ovary underpins both
benign and malignant cell proliferation. Normally, high
levels of telomerase activity are a hallmark of cancer,
including ovarian epithelial carcinoma [21]. Accumulat-
ing data indicate that telomerase activation is an early
event in ovarian carcinogenesis [22-25]. As expected,
the telomerase activities were positive in both SKOV-3
and ES-2 cells and negative in HUVECs. At the same
time, the telomerase activities in ELs from SKOV-3 cells
with or without Sirolimus treatment were also positive
while those in ELs from ES-2 cells with or without Siro-
limus were negative. The difference of telomerase activ-
ity between the two ELs may contribute to the different
proliferative behaviors of the two cells.
To explore the underlying mechanisms of the SKOV-3
and ES-2 changed to ELs by hypoxia treatment, we
detected the expression of some relative genes in the
SKOV-3, ES-2, SKOV-3 ELs, ES-2 ELs, with or without
Sirolimus, and HUVECs. As Fig. 3 shown, compared
with the original cancer cells, the ELs represented the
elevated HIF-1a, VEGF, VEGF receptor-2 (Flk-1) and
p53 mRNA expression, while the expression of Cyclin
D1 was decreased. Our and others’ studies have indi-
cated that HIF-1a played a vital role for the angiogen-
esis and VM under hypoxia [11,26-28]. To determine
the origin of the change in VEGF and Flk-1 expression,
we used the Sirolimus to inhibit the activity of HIF-1a.
Sirolmus, known as rapamycin, is proved to be as the
inhibitor of HIF-1a [26,29,30]. Consistent with other
researches, the changes in the expression of VEGF, Flk-
1 and Cyclin D1 were HIF-1a transcriptional dependent
[10,31]. However, the change in the expression of p53
was HIF-1a transcriptional independent.
Conclusion
In summary, the ovarian cancer cells could be induced
into ELs which seemed similarly to progenitor endothe-
lial cells by hypoxia. After induced, the ELs would get
some characteristics of endothelial cells and would lose
some malignant characteristics of the original cancer
cells. The increased expression of HIF-1a, and HIF-1a
depended VEGF and Flk-1 might contribute to the VM
and the vasculogenesis. During the transition, HIF-1a
took an important role in the molecular mechanisms,
while there still has other HIF-1a-independent mechan-
ism in this process.
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